Short-Term Effect of HAART on Blood Pressure in HIV-Infected Individuals
- 1 February 2008
- journal article
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 9 (1) , 52-60
Abstract
Purpose: Use of highly active antiretroviral therapy (HAART) is associated with coronary heart disease (CHD) risk and may lead to the development of hypertension (HTN). The purpose of this study was to determine the short-term effect of HAART on the blood pressure. Method: A prospective, standardized, observational study of HIV-infected persons starting protease inhibitor (PI) or non-PI-based HAART. HIV-infected individuals not on HAART served as controls. Standardized blood pressure readings were taken using American Heart Association recommended techniques at baseline, 4–6 weeks, and ⩾6 months. Results: 63 subjects were enrolled. 51 subjects completed all study visits. There were no significant differences in baseline demographic or clinical characteristics between the PI (n = 16), non-PI (n = 20), or control (n = 15) participants. Two subjects developed HTN during the study. There were no significant changes in systolic, diastolic, or mean arterial pressures after 4–6 weeks or 6 months between or within groups. Conclusion: Initiation of HAART did not significantly alter blood pressure within the first 6 months of use. Prior reported associations of hypertension with HAART may be related to techniques used to measure blood pressure, specific antiretroviral agents, longer term use of HAART, or the presence of other risk factors typically associated with the development of HTN.Keywords
This publication has 20 references indexed in Scilit:
- Coronary heart disease in HIV-infected patientsCurrent HIV/AIDS Reports, 2005
- Changing mortality rates and causes of death for HIV‐infected individuals living in Southern Alberta, Canada from 1984 to 2003HIV Medicine, 2005
- HIV, Metabolic Syndrome X, Inflammation, Oxidative Stress, and Coronary Heart Disease Risk : Role of Protease Inhibitor ExposureCardiovascular Toxicology, 2004
- Dyslipidaemia associated with antiretroviral therapy in HIV-infected patientsJournal of Antimicrobial Chemotherapy, 2003
- Combination Antiretroviral Therapy and the Risk of Myocardial InfarctionNew England Journal of Medicine, 2003
- Human Immunodeficiency Virus/Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome: Clinical Presentation, Pathophysiology, and Therapeutic StrategiesThe Journal of Clinical Endocrinology & Metabolism, 2003
- Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular diseaseAIDS, 2003
- HIV Disease and Advanced AgeDrugs & Aging, 2002
- Effectiveness of Potent Antiretroviral Therapy on Time to AIDS and Death in Men With Known HIV Infection DurationJAMA, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998